Search

Indeed, one very recent study found that a patient with the T878A mutation and a second patient with the functionally related T878S mutation did not respond to enzalutamide.[6] To our knowledge, this is the first report of clinical benefit achieved from AR T878A targeting by the AR antagonist darolutamide. Of note, the only US Food and Drug Administration-approved second-generation antiandrogen for patients with AA-resistant CRPC is enzalutamide, and in vitro studies of the T878A-mutant AR suggest that this patient would have responded similarly to enzalutamide or apalutmide. [Extracted from the article]

Indeed, one very recent study found that a patient with the T878A mutation and a second patient with the functionally related T878S mutation did not respond to enzalutamide.[6] To our knowledge, this is the first report of clinical benefit achieved from AR T878A targeting by the AR antagonist darolutamide. Of note, the only US Food and Drug Administration-approved second-generation antiandrogen for patients with AA-resistant CRPC is enzalutamide, and in vitro studies of the T878A-mutant AR suggest that this patient would have responded similarly to enzalutamide or apalutmide. [Extracted from the article]